Literature DB >> 2896958

T lymphocyte activation in acute severe asthma.

C J Corrigan1, A Hartnell, A B Kay.   

Abstract

T lymphocyte subsets and lymphocyte activation markers in the peripheral blood were assessed in patients admitted to hospital with acute severe asthma (status asthmaticus). Measurements were made on admission, day 3, and day 7 (or on discharge from hospital if this was sooner). The results were compared with 3 control groups (mild asthma, chronic obstructive airways disease, and normal individuals). The percentages of CD4-positive and CD8-positive T lymphocytes, and the CD4/CD8 ratios, were similar in the patients with acute severe asthma and the control groups, and were within the normal range. In contrast, patients with acute severe asthma had significant increases, compared with control subjects, of three surface proteins associated with T lymphocyte activation: interleukin-2 receptor (IL-2R); class II histocompatibility antigen (HLA-DR); and "very late activation" antigen (VLA-1). The IL-2R-positive T lymphocytes were exclusively of the CD4 "helper-inducer" phenotype. The percentages of IL-2R-positive and HLA-DR-positive (but not VLA-1-positive) lymphocytes tended to decrease as the patients were treated and clinically improved, although these values remained raised above control values for the observation period. Cell-mediated immunity may be causally related to the pathogenesis of acute severe asthma.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2896958     DOI: 10.1016/s0140-6736(88)91951-4

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  53 in total

Review 1.  Th2 cells and GATA-3 in asthma: new insights into the regulation of airway inflammation.

Authors:  A Ray; L Cohn
Journal:  J Clin Invest       Date:  1999-10       Impact factor: 14.808

Review 2.  Cytokines in asthma.

Authors:  K F Chung; P J Barnes
Journal:  Thorax       Date:  1999-09       Impact factor: 9.139

3.  Flow cytometry in the exploration of the physiopathology of occupational lung disease.

Authors:  A D Curran
Journal:  Occup Environ Med       Date:  1999-11       Impact factor: 4.402

4.  Sputum T lymphocytes in asthma, COPD and healthy subjects have the phenotype of activated intraepithelial T cells (CD69+ CD103+).

Authors:  M J Leckie; G R Jenkins; J Khan; S J Smith; C Walker; P J Barnes; T T Hansel
Journal:  Thorax       Date:  2003-01       Impact factor: 9.139

5.  Low MW B-cell growth factor potentiates histamine release from human basophil leucocytes.

Authors:  A Tedeschi; M G Roncarolo; M Lorini; A Miadonna
Journal:  Immunology       Date:  1991-06       Impact factor: 7.397

Review 6.  Determinants and regulating processes in bronchial hyperreactivity.

Authors:  H J Neijens
Journal:  Lung       Date:  1990       Impact factor: 2.584

7.  Blocking cyclophilins in the chronic phase of asthma reduces the persistence of leukocytes and disease reactivation.

Authors:  Erik J Stemmy; Molly A Balsley; Rosalyn A Jurjus; Jesse M Damsker; Michael I Bukrinsky; Stephanie L Constant
Journal:  Am J Respir Cell Mol Biol       Date:  2011-04-14       Impact factor: 6.914

8.  Airway epithelial cell expression of interleukin-6 in transgenic mice. Uncoupling of airway inflammation and bronchial hyperreactivity.

Authors:  B F DiCosmo; G P Geba; D Picarella; J A Elias; J A Rankin; B R Stripp; J A Whitsett; R A Flavell
Journal:  J Clin Invest       Date:  1994-11       Impact factor: 14.808

9.  Increased adhesion of human monocytes to IL-4-stimulated human venous endothelial cells via CD11/CD18, and very late antigen-4 (VLA-4)/vascular cell adhesion molecule-1 (VCAM-1)-dependent mechanisms.

Authors:  E M Verdegaal; H Beekhuizen; I Blokland; R van Furth
Journal:  Clin Exp Immunol       Date:  1993-08       Impact factor: 4.330

10.  Intercellular adhesion molecule-1 is upregulated on peripheral blood T lymphocyte subsets in dual asthmatic responders.

Authors:  V De Rose; G Rolla; C Bucca; P Ghio; M Bertoletti; P Baderna; E Pozzi
Journal:  J Clin Invest       Date:  1994-11       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.